Drug intelligence / Profile preview

LVRNA021

Development stage: Phase 3
Lead developer: AIM Vaccine Co.
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

LVRNA021 is a bivalent mRNA vaccine developed by AIM Vaccine Co., Ltd. for the prevention of COVID-19. It is designed as a booster vaccination for individuals aged 18 years and older who have previously received SARS-CoV-2 vaccines. The vaccine utilizes messenger RNA technology to encode the spike protein of two different SARS-CoV-2 variants, aiming to provide broader protection against evolving strains. It has been evaluated in Phase 1, Phase 2, and Phase 3 clinical trials in China, focusing on safety, tolerability, and immunogenicity as a sequential booster.

Other names: SARS-CoV-2 Bivalent mRNA VaccineSARS-CoV2 Bivalent mRNA VaccineSARS-CoV 2 Bivalent mRNA VaccineCOVID-19 mRNA Vaccine, Bivalent

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on LVRNA021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LVRNA021.

Explore the full profile